Comparison Between Simple Batch and Fed-Batch Bioreactor Cultivation of Recombinant BCG
<b>Background/Objectives</b>: Tuberculosis continues to be a significant global health concern, causing 1.3 million deaths in 2022, particularly affecting children under 5 years old. The Bacillus Calmette-Guérin (BCG) vaccine, developed in 1921, remains the primary defense against tuberculosis but requires modernized production methods. The recombinant BCG-pertussis strain shows potential in providing dual protection against tuberculosis and whooping cough, especially for vulnerable newborns, and enhanced efficacy against bladder cancer. Implementing submerged cultivation techniques for rBCG-pertussis production can offer increased productivity and standardization. <b>Methods</b>: This study explores a fed-batch cultivation strategy with pH-stat control to feed L-glutamic acid through the acid pump into 1 L bioreactor. Three pH values were evaluated for fed-batch and a simple batch without pH control was done for comparison. The viable cell concentration was compared before and after freeze-drying samples harvested during the cultures. <b>Results</b>: L-glutamic acid was identified as the preferred substrate for rBCG-pertussis. While the fed-batch strategy did not enhance the maximum specific growth rate compared to simple batch cultivation, it did improve the specific growth rate after day 4 in the pH 7.4-controlled fed-batch cultures, thereby reducing the cultivation time. Fed-batch cultures controlled at three pH levels exhibited lower optical density than the simple batch, although the viable cell counts were similar. Notably, samples harvested after day 8 from the simple batch cultures showed a reduction in CFU/mL after freeze-drying, whereas all fed-batch samples exhibited high recovery of viable cell counts post lyophilization. <b>Conclusions</b>: The additional glutamate supplied to the fed-batch cultures may have protected the cells during the lyophilization process.
Authors
- Ryhára Dias Batista (ORCID: https://orcid.org/0000-0003-2397-3318)
- Patrícia Zorzete
- Viviane Maimoni Gonçalves (ORCID: https://orcid.org/0000-0002-0980-8116)
- Sofia Mendes (ORCID: https://orcid.org/0000-0003-2594-852X)
- Maria Carolina Pereira Gonçalves (ORCID: https://orcid.org/0000-0003-4510-1393)
- Luciana C. C. Leite (ORCID: https://orcid.org/0000-0003-0156-1312)
- Vitoria A. P. Aiex
Institutions
- Universidade de São Paulo (BR)
- Instituto Butantan (BR)
Publication Details
- Journal
- Pharmaceutics
- Published
- 2024-11-11
- DOI
- https://doi.org/10.3390/pharmaceutics16111433
- Primary Topic
- Cancer Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Fundação Butantan